Cited by 62HIV/AIDS drug development and treatmentHIV Research and TreatmentBiochemical and Molecular Research

Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase

Open access
Corona, Angela, Masaoka, Takashi, Tocco, Graziella, Tramontano, Enzo, Le Grice, Stuart FJ·2013·Future Medicinal Chemistry

Abstract

Despite the wealth of information available for the reverse transcriptase (RT)-associated ribonuclease H (RNaseH) domain of lentiviruses, gammaretroviruses and long terminal repeat containing retrotransposons, exploiting this information in the form of an RNaseH inhibitor with high specificity and low cellular toxicity has been disappointing. However, it is now becoming increasingly evident that the two-subunit HIV-1 RT is a highly versatile enzyme, undergoing major structural alterations in order to interact with, position and ultimately hydrolyze the RNA component of an RNA/DNA hybrid. Thus, in addition to targeting the RNaseH active site, identifying small molecules that bind elsewhere and disrupt catalysis allosterically by impairing conformational flexibility is gaining increased attention. This review summarizes current progress towards development of both active site and allosteric RNaseH inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4155/fmc.13.178

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several pharmacophores for ribonuclease H active-site inhibitors are diketo acid, N-hydroxyimide, hydroxytropolone, pyrimidinol carboxylic acid, N-hydroxy naphthyridinone, pyrido-pyrimidinone, nitrofuran-2-carboxylic acid, and thiocarbamates.

    “Several pharmacophores for RNH active site inhibitors are: diketo acid, N-hydroxyimide, hydroxytropolone, pyrimidinol carboxylic acid, N-hydroxy naphthyridinone, pyrido-pyrimidinone, nitrofuran-2-carboxylic acid and thiocarbamates [31,32].”

    From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [32]

    The Metal-chelating active site inhibitors sections discuss diketo acids, N-hydroxyimides, hydroxytropolones, pyrimidinol carboxylic acids, N-hydroxynaphthyridinones, nitrofuran derivatives, and thiocarbamates. The copy does not identify a pyrido-pyrimidinone active-site inhibitor; it instead discusses thienopyrimidinones under Allosteric RNaseH inhibitors. Page numbers were not available in the indexed passages. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Significant progress has been made in developing active-site ribonuclease H inhibitors.

    “During the past several years, significant progress has been made in the development of active-site RNH inhibitors [32-35].”

    From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [32]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [3]Schatz O, Cromme F, Naas T Inactivation of the RNaseH domain of HIV-1 reverse transcriptase blocks viral infectivity In: Oncogenesis and AIDS. Papas TS (Ed.). Portfolio Publishing Company, TX, USA, 293– 303 (1990).

Cited by

Sorted by citations

Authors
Corona, A., Masaoka, T., Tocco, G., Tramontano, E., & Le Grice, S. F.
Affiliations
  • University of Cagliari (IT)
  • National Cancer Institute (US)
  • RT Biochemistry Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD21702, USA
Venue
Future Medicinal Chemistry
Published
2013-11-21
Volume
5
Issue
18
Pages
2127-2139
ISSN
  • 1756-8919 (ISSN-L)
  • 1756-8927
OpenAlex
W2024192530
Cited by
54
References
61
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 3 · 2021: 6 · 2020: 8 · 2019: 4 · 2018: 4 · 2017: 5 · 2016: 9 · 2015: 3 · 2014: 4
FWCI
0.82
Type
journal article
Language
en
Open access
Locations
  • Future Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
Funders
Ministero dell ‘Universita, dell’ Istruzione e della Ricerca (LR 7/2007 CRP-24915 and MIUR PRIN 2012)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
HIV-1 reverse transcriptase, RNase H, allosteric inhibitors, active-site-directed inhibitors, conformational flexibility, lentivirus, gammaretrovirus, retrotransposons, small molecule inhibitors
MeSH terms
Allosteric Regulation, Enzyme Inhibitors, Hydrolysis, Ribonuclease H, Catalytic Domain, HIV Reverse Transcriptase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review